Journal of Neurogastroenterology and Motility

The Korean Society of Neurogastroenterology and Motility (대한소화기 기능성질환 운동학회)
권호 표지
DOI QR코드

DOI QR Code

Expression of Toll-like Receptors, Pro-, and Anti-inflammatory Cytokines in Relation to Gut Microbiota in Irritable Bowel Syndrome: The Evidence for Its Micro-organic Basis

  • Shukla, Ratnakar (Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Ghoshal, Ujjala (Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Ranjan, Prabhat (Department of Microbiology, Sanjay Gandhi Postgraduate Institute of Medical Sciences) ;
  • Ghoshal, Uday C (Department of Gastroenterology, Sanjay Gandhi Postgraduate Institute of Medical Sciences)
  • Received : 2018.07.23
  • Accepted : 2018.08.24
  • Published : 2018.10.30
⟨ Previous Next ⟩

Abstract

Background/Aims A Subset of patients with irritable bowel syndrome (IBS) may have mild inflammation due to immune activation. Toll-like receptors (TLRs) and cytokines may cause intestinal inflammation. We studied their expression in relation to gut microbiota. Methods Expression of TLRs and cytokines was assessed in 47 IBS patients (Rome III) and 25 controls using quantitative real-time polymerase chain reaction. Immunohistochemistry was further performed to confirm the expression of TLR-4 and TLR-5. Results Of 47 patients with IBS, 20 had constipation (IBS-C), 20 diarrhea (IBS-D), and 7 unclassified (IBS-U). The mRNA levels of TLR-4 and TLR-5 were up-regulated in IBS patients than controls (P = 0.013 and P < 0.001, respectively). Expression of TLR-4 and TLR-5 at protein level was 4.2-folds and 6.6-folds higher in IBS-D than controls. The mRNA levels of IL-6 (P = 0.003), C-X-C motif chemokine ligand 11 (CXCL-11) (P < 0.001) and C-X-C motif chemokine receptor 3 (CXCR-3) (P < 0.001) were higher among IBS patients than controls. Expression of IL-6 (P = 0.002), CXCL-11 (P < 0.001), and CXCR-3 (P < 0.001) were up-regulated and IL-10 (P = 0.012) was down-regulated in IBS-D patients than controls. Positive correlation was seen between TLR-4 and IL-6 (P = 0.043), CXCR-3, and CXCL-11 (P = 0.047), and IL-6 and CXCR-3 (P = 0.003). Stool frequency per week showed positive correlation with mRNA levels of TLR-4 (P = 0.016) and CXCR-3 (P = 0.005), but inversely correlated with IL-10 (P = 0.002). Copy number of Lactobacillus (P = 0.045) and Bifidobacterium (P = 0.011) showed correlation with IL-10 in IBS-C, while Gram-positive (P = 0.031) and Gram-negative bacteria (P = 0.010) showed correlation with CXCL-11 in IBS-D patients. Conclusions Altered immune activation in response to dysbiotic microbiota may promote intestinal inflammation in a subset of patients with IBS.

Keywords

Acknowledgement

Supported by : Department of Science and Technology

References

  1. Ghoshal UC, Shukla R, Ghoshal U, Gwee KA, Ng SC, Quigley EM. The gut microbiota and irritable bowel syndrome: friend or foe? Int J Inflam 2012;2012:151085.
  2. Ghoshal UC, Abraham P, Bhatt C, et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian society of gastroenterology task force. Indian J Gastroenterol 2008;27:22-28.
  3. Shukla R, Ghoshal U, Dhole TN, Ghoshal UC. Fecal microbiota in patients with irritable bowel syndrome compared with healthy controls using real-time polymerase chain reaction: an evidence of dysbiosis. Dig Dis Sci 2015;60:2953-2962. https://doi.org/10.1007/s10620-015-3607-y
  4. Brint EK, MacSharry J, Fanning A, Shanahan F, Quigley EM. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-336. https://doi.org/10.1038/ajg.2010.438
  5. Hajela N, Ramakrishna BS, Nair GB, Abraham P, Gopalan S, Ganguly NK. Gut microbiome, gut function, and probiotics: implications for health. Indian J Gastroenterol 2015;34:93-107. https://doi.org/10.1007/s12664-015-0547-6
  6. Ohman L, Tornblom H, Simren M. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol 2015;12:36-49. https://doi.org/10.1038/nrgastro.2014.200
  7. Ortiz-Lucas M, Saz-Peiro P, Sebastian-Domingo JJ. Irritable bowel syndrome immune hypothesis. Part two: the role of cytokines. Rev Esp Enferm Dig 2010;102:711-717.
  8. Belmonte L, Beutheu Youmba S, Bertiaux-Vandaele N, et al. Role of toll like receptors in irritable bowel syndrome: differential mucosal immune activation according to the disease subtype. PLoS One 2012;7:e42777. https://doi.org/10.1371/journal.pone.0042777
  9. Abreu MT. Toll-like receptor signalling in the intestinal epithelium: how bacterial recognition shapes intestinal function. Nat Rev Immunol 2010;10:131-144. https://doi.org/10.1038/nri2707
  10. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ. The role of epithelial tolllike receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 2008;83:493-498. https://doi.org/10.1189/jlb.0607358
  11. Cario E. Bacterial interactions with cells of the intestinal mucosa: toll-like receptors and NOD2. Gut 2005;54:1182-1193. https://doi.org/10.1136/gut.2004.062794
  12. McKernan DP, Gaszner G, Quigley EM, Cryan JF, Dinan TG. Altered peripheral toll-like receptor responses in the irritable bowel syndrome. Aliment Pharmacol Ther 2011;33:1045-1052. https://doi.org/10.1111/j.1365-2036.2011.04624.x
  13. Frosali S, Pagliari D, Gambassi G, Landolfi R, Pandolfi F, Cianci R. [How the intricate interaction among toll-like receptors, microbiota, and intestinal immunity can influence gastrointestinal pathology.] J Immunol Res 2015;2015:489821. [Chinese]
  14. Dillon S, Agrawal A, Van Dyke T, et al. A toll-like receptor 2 ligand stimulates Th2 responses in vivo, via induction of extracellular signalregulated kinase mitogen-activated protein kinase and c-fos in dendritic cells. J Immunol 2004;172:4733-4743. https://doi.org/10.4049/jimmunol.172.8.4733
  15. Wong CK, Wong PT, Tam LS, Li EK, Chen DP, Lam CW. Activation profile of toll-like receptors of peripheral blood lymphocytes in patients with systemic lupus erythematosus. Clin Exp Immunol 2010;159:11-22. https://doi.org/10.1111/j.1365-2249.2009.04036.x
  16. Liu Z, Chen X, Wang X, et al. Chemokine CXCL11 links microbial stimuli to intestinal inflammation. Clin Exp Immunol 2011;164:396-406. https://doi.org/10.1111/j.1365-2249.2011.04382.x
  17. Tokuyama H, Ueha S, Kurachi M, et al. The simultaneous blockade of chemokine receptors CCR2, CCR5 and CXCR3 by a non-peptide chemokine receptor antagonist protects mice from dextran sodium sulfatemediated colitis. Int Immunol 2005;17:1023-1034. https://doi.org/10.1093/intimm/dxh284
  18. Danese S, Gao B. Interleukin-6: a therapeutic Jekyll and Hyde in gastrointestinal and hepatic diseases. Gut 2010;59:149-151. https://doi.org/10.1136/gut.2008.173534
  19. Bashashati M, Rezaei N, Shafieyoun A, et al. Cytokine imbalance in irritable bowel syndrome: a systematic review and meta-analysis. Neurogastroenterol Motil 2014;26:1036-1048. https://doi.org/10.1111/nmo.12358
  20. Ghoshal UC, Gwee KA, Chen M, et al. Development, translation and validation of enhanced asian rome III questionnaires for diagnosis of functional bowel diseases in major asian languages: a rome foundationasian neurogastroenterology and motility association working team report. J Neurogastroenterol Motil 2015;21:83-92. https://doi.org/10.5056/jnm14045
  21. Xu J, Yang Y, Sun J, et al. Expression of toll-like receptors and their association with cytokine responses in peripheral blood mononuclear cells of children with acute rotavirus diarrhoea. Clin Exp Immunol 2006;144:376-381. https://doi.org/10.1111/j.1365-2249.2006.03079.x
  22. Schaefer TM, Desouza K, Fahey JV, Beagley KW, Wira CR. toll-like receptor (TLR) expression and TLR-mediated cytokine/chemokine production by human uterine epithelial cells. Immunology 2004;112:428-436. https://doi.org/10.1111/j.1365-2567.2004.01898.x
  23. Jin SH, Kang HY. Activation of toll-like receptors 1, 2, 4, 5, and 7 on human melanocytes modulate pigmentation. Ann Dermatol 2010;22:486-489. https://doi.org/10.5021/ad.2010.22.4.486
  24. Zhou Y, Wei Y, Wang L, et al. Decreased adiponectin and increased inflammation expression in epicardial adipose tissue in coronary artery disease. Cardiovasc Diabetol 2011;10:2. https://doi.org/10.1186/1475-2840-10-2
  25. Hida N, Shimoyama T Jr, Neville P, et al. Increased expression of IL-10 and IL-12 (p40) mRNA in Helicobacter pylori infected gastric mucosa: relation to bacterial cag status and peptic ulceration. J Clin Pathol 1999;52:658-664. https://doi.org/10.1136/jcp.52.9.658
  26. Schroepf S, Kappler R, Brand S, et al. Strong overexpression of CXCR3 axis components in childhood inflammatory bowel disease. Inflamm Bowel Dis 2010;16:1882-1890. https://doi.org/10.1002/ibd.21312
  27. Kimang'a A, Revathi G, Kariuki S, et al. IL-17A and IL-17F gene expression is strongly induced in the mucosa of H. pylori-infected subjects from Kenya and Germany. Scand J Immunol 2010;72:522-528. https://doi.org/10.1111/j.1365-3083.2010.02469.x
  28. Stanislawowski M, Wierzbicki PM, Golab A, et al. Decreased toll-like receptor-5 (TLR-5) expression in the mucosa of ulcerative colitis patients. J Physiol Pharmacol 2009;60(suppl 4):71-75.
  29. Liang WJ, Zhang G, Luo HS, Liang LX, Huang D, Zhang FC. Tryptase and protease-activated receptor 2 expression levels in irritable bowel syndrome. Gut Liver 2016;10:382-390.
  30. Ipci K, Altintoprak N, Muluk NB, Senturk M, Cingi C. The possible mechanisms of the human microbiome in allergic diseases. Eur Arch Otorhinolaryngol 2017;274:617-626. https://doi.org/10.1007/s00405-016-4058-6
  31. Cario E, Podolsky DK. Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease. Infect Immun 2000;68:7010-7017. https://doi.org/10.1128/IAI.68.12.7010-7017.2000
  32. Wells JM, Rossi O, Meijerink M, van Baarlen P. Epithelial crosstalk at the microbiota-mucosal interface. Proc Natl Acad Sci USA 2011;108(suppl 1):4607-4614. https://doi.org/10.1073/pnas.1000092107
  33. McKernan DP, Nolan A, Brint EK, et al. Toll-like receptor mRNA expression is selectively increased in the colonic mucosa of two animal models relevant to irritable bowel syndrome. PLoS One 2009;4:e8226. https://doi.org/10.1371/journal.pone.0008226
  34. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol 2003;170:5165-5175. https://doi.org/10.4049/jimmunol.170.10.5165
  35. Thompson-Chagoyan OC, Maldonado J, Gil A. Aetiology of inflammatory bowel disease (IBD): role of intestinal microbiota and gut-associated lymphoid tissue immune response. Clin Nutr 2005;24:339-352. https://doi.org/10.1016/j.clnu.2005.02.009
  36. Darkoh C, Comer L, Zewdie G, Harold S, Snyder N, Dupont HL. Chemotactic chemokines are important in the pathogenesis of irritable bowel syndrome. PLoS One 2014;9:e93144. https://doi.org/10.1371/journal.pone.0093144
  37. Hughes PA, Zola H, Penttila IA, Blackshaw LA, Andrews JM, Krumbiegel D. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms? Am J Gastroenterol 2013;108:1066-1074. https://doi.org/10.1038/ajg.2013.120
  38. Chang L, Sundaresh S, Elliott J, et al. Dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis in irritable bowel syndrome. Neurogastroenterol Motil 2009;21:149-159. https://doi.org/10.1111/j.1365-2982.2008.01171.x
  39. Jardi F, Fernandez-Blanco JA, Martinez V, Vergara P. Plasticity of dorsal root ganglion neurons in a rat model of post-infectious gut dysfunction: potential implication of nerve growth factor. Scand J Gastroenterol 2014;49:1296-1303. https://doi.org/10.3109/00365521.2014.958524
  40. Chang L, Adeyemo M, Karagiannides I, et al. Serum and colonic mucosal immune markers in irritable bowel syndrome. Am J Gastroenterol 2012;107:262-272. https://doi.org/10.1038/ajg.2011.423
  41. De Silva AP, Nandasiri SD, Hewavisenthi J, et al. Subclinical mucosal inflammation in diarrhea-predominant irritable bowel syndrome (IBS) in a tropical setting. Scand J Gastroenterol 2012;47:619-624.
  42. van der Veek PP, van den Berg M, de Kroon YE, Verspaget HW, Masclee AA. Role of tumor necrosis factor-$\alpha$ and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-2516. https://doi.org/10.1111/j.1572-0241.2005.00257.x
  43. Geiger B, Wenzel J, Hantschke M, Haase I, Stander S, von Stebut E. Resolving lesions in human cutaneous leishmaniasis predominantly harbour chemokine receptor CXCR3-positive T helper 1/T cytotoxic type 1 cells. Br J Dermatol 2010;162:870-874.
  44. Bao CR, Tang GY, Zhang XP, Quan ZW. Lentivirus-mediated gene transfer of small interfering RNA against the chemokine receptor CXCR3 suppresses cytokine indicators of acute graft rejection in a rat model. J Int Med Res 2010;38:1113-1120. https://doi.org/10.1177/147323001003800340
  45. Keszthelyi D, Troost FJ, Jonkers DM, et al. Serotonergic reinforcement of intestinal barrier function is impaired in irritable bowel syndrome. Aliment Pharmacol Ther 2014;40:392-402. https://doi.org/10.1111/apt.12842
  46. Arebi N, Gurmany S, Bullas D, Hobson A, Stagg A, Kamm M. Review article: the psychoneuroimmunology of irritable bowel syndrome--an exploration of interactions between psychological, neurological and immunological observations. Aliment Pharmacol Ther 2008;28:830-840. https://doi.org/10.1111/j.1365-2036.2008.03801.x
  47. Tache Y, Martinez V, Wang L, Million M. CRF1 receptor signaling pathways are involved in stress-related alterations of colonic function and viscerosensitivity: implications for irritable bowel syndrome. Br J Pharmacol 2004;141:1321-1330. https://doi.org/10.1038/sj.bjp.0705760
  48. Malinen E, Rinttila T, Kajander K, et al. Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 2005;100:373-382. https://doi.org/10.1111/j.1572-0241.2005.40312.x
  49. Kerckhoffs AP, Samsom M, van der Rest ME, et al. Lower Bifidobacteria counts in both duodenal mucosa-associated and fecal microbiota in irritable bowel syndrome patients. World J Gastroenterol 2009;15:2887-2892. https://doi.org/10.3748/wjg.15.2887
  50. Borchers AT, Selmi C, Meyers FJ, Keen CL, Gershwin ME. Probiotics and immunity. J Gastroenterol 2009;44:26-46. https://doi.org/10.1007/s00535-008-2296-0
  51. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-551. https://doi.org/10.1053/j.gastro.2004.11.050
  52. Seth AK, Rawal P, Bagga R, Jain P. Successful colonoscopic fecal microbiota transplantation for active ulcerative colitis: first report from India. Indian J Gastroenterol 2016;35:393-395. https://doi.org/10.1007/s12664-016-0696-2
  53. Subramanyam C, Pratap N, Gandham P, et al. Influence of probiotic administration on the fecal microbiota in diarrhea-predominant irritable bowel syndrome. Indian J Gastroenterol 2015;34:275-276. https://doi.org/10.1007/s12664-015-0545-8
  54. Vaishnavi C. Fecal microbiota transplantation for management of Clostridium difficile infection. Indian J Gastroenterol 2014;33:301-307. https://doi.org/10.1007/s12664-014-0459-x

Cited by

  1. Overlapping irritable bowel syndrome and inflammatory bowel disease vol.65, pp.2, 2018, https://doi.org/10.23736/s1121-421x.19.02559-5
  2. Mechanisms by Which the Gut Microbiota Influences Cytokine Production and Modulates Host Inflammatory Responses vol.39, pp.7, 2019, https://doi.org/10.1089/jir.2019.0011
  3. Second Asian Consensus on Irritable Bowel Syndrome vol.25, pp.3, 2018, https://doi.org/10.5056/jnm19041
  4. Increasing Evidence That Irritable Bowel Syndrome and Functional Gastrointestinal Disorders Have a Microbial Pathogenesis vol.10, pp.None, 2018, https://doi.org/10.3389/fcimb.2020.00468
  5. Gut microbiota abnormalities, small intestinal bacterial overgrowth, and non-alcoholic fatty liver disease: An emerging paradigm vol.39, pp.1, 2018, https://doi.org/10.1007/s12664-020-01027-w
  6. Circulating microbiota-derived metabolites: a “liquid biopsy? vol.44, pp.4, 2020, https://doi.org/10.1038/s41366-019-0430-0
  7. Marshall and Warren Lecture 2019: A paradigm shift in pathophysiological basis of irritable bowel syndrome and its implication on treatment vol.35, pp.5, 2018, https://doi.org/10.1111/jgh.15032
  8. Prospects for the use of biomarkers in the diagnosis of irritable bowel syndrome vol.3, pp.None, 2018, https://doi.org/10.31146/1682-8658-ecg-175-3-94-101
  9. Colonic Gene Expression and Fecal Microbiota in Diarrhea-predominant Irritable Bowel Syndrome: Increased Toll-like Receptor 4 but Minimal Inflammation and no Response to Mesalazine vol.27, pp.2, 2021, https://doi.org/10.5056/jnm20205
  10. The Potential Protective Role of RUNX1 in Nonalcoholic Fatty Liver Disease vol.22, pp.10, 2018, https://doi.org/10.3390/ijms22105239
  11. Syndrome de l’intestin irritable : Rôle du microbiote intestinal vol.37, pp.6, 2021, https://doi.org/10.1051/medsci/2021095
  12. Gut microbiota dysbiosis in functional gastrointestinal disorders: Underpinning the symptoms and pathophysiology vol.5, pp.9, 2018, https://doi.org/10.1002/jgh3.12528
  13. Functional gastrointestinal disorders. Overlap syndrome Clinical guidelines of the Russian Scientific Medical Society of Internal Medicine and Gastroenterological Scientific Society of Russia vol.8, pp.None, 2021, https://doi.org/10.31146/1682-8658-ecg-192-8-5-117